Cardiovascular comorbidities as predictors for severe COVID-19 infection or death.


Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 07 07 2020
revised: 05 10 2020
accepted: 14 10 2020
pubmed: 28 10 2020
medline: 27 3 2021
entrez: 27 10 2020
Statut: ppublish

Résumé

Pre-existing cardiovascular diseases (CVDs) have been proposed to identify patients at higher risk of adverse coronavirus disease 2019 (COVID-19) outcomes, but existing evidence is conflicting. Thus, it is unclear whether pre-existing CVDs are independently important predictors for severe COVID-19. In a nationwide Danish cohort of hospital-screened COVID-19 patients aged ≥40, we investigated if pre-existing CVDs predict the 30-day risk of (i) composite outcome of severe COVID-19 and (ii) all-cause mortality. We estimated 30-day risks using a Cox regression model including age, sex, each CVD comorbidity, chronic obstructive pulmonary disease-asthma, diabetes, and chronic kidney disease. To illustrate CVD comorbidities' importance, we evaluated the predicted risks of death and severe infection, for each sex, along ages 40-85. In total, 4090 COVID-19 hospital-screened patients were observed as of 26 August 2020; 22.1% had ≥1 CVD, 23.7% had severe infection within 30 days and 12.6% died. Predicted risks of both outcomes at age 75 among men with single CVD comorbidities did not differ in clinically meaningful amounts compared with men with no comorbidities risks for the composite outcome of severe infection; women with heart failure (28.2%; 95% CI 21.1-37.0%) or atrial fibrillation (30.0%; 95% CI: 24.2-36.9%) showed modest increases compared with women with no comorbidities (24.0%; 95% CI: 21.4-26.9%). The results showing only modest effects of CVDs on increased risks of poor COVID-19 outcomes are important in allowing public health authorities and clinicians to provide more tailored guidance to cardiovascular patients, who have heretofore been grouped together as high risk due to their disease status.

Identifiants

pubmed: 33107909
pii: 5941478
doi: 10.1093/ehjqcco/qcaa081
pmc: PMC7665490
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

172-180

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

N Engl J Med. 2020 Mar 26;382(13):1194-1196
pubmed: 32074416
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
CMAJ. 2007 Jun 19;176(13):1827-32
pubmed: 17576979
Clin Epidemiol. 2019 Jul 12;11:563-591
pubmed: 31372058
Intensive Care Med. 2020 Jun;46(6):1294-1297
pubmed: 32253449
Eur Heart J. 2020 Jun 1;41(32):3072-3079
pubmed: 32578859
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Lancet Infect Dis. 2015 Jul;15(7):825-32
pubmed: 25921597
Circ Cardiovasc Qual Outcomes. 2020 Apr;13(4):e006631
pubmed: 32182131
JAMA Intern Med. 2020 Jun 1;180(6):817-818
pubmed: 32275292
BMJ. 2012 Jan 25;344:e356
pubmed: 22279115
Circ Heart Fail. 2020 Jun;13(6):e007274
pubmed: 32482087
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
JAMA Intern Med. 2020 Jul 1;180(7):927-928
pubmed: 32259190
PLoS One. 2020 Aug 14;15(8):e0237131
pubmed: 32797054
Eur Heart J. 2020 Jun 7;41(22):2083-2088
pubmed: 32412631
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
J Gen Intern Med. 2020 Sep;35(9):2801-2803
pubmed: 32583345
Heart. 2020 Aug;106(15):1148-1153
pubmed: 32451362
BMJ Open. 2016 Nov 18;6(11):e012832
pubmed: 27864249
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
BMJ. 2020 May 22;369:m1985
pubmed: 32444460

Auteurs

Matthew Phelps (M)

The Danish Heart Foundation, Copenhagen, Denmark.

Daniel Mølager Christensen (DM)

The Danish Heart Foundation, Copenhagen, Denmark.

Thomas Gerds (T)

Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.

Emil Fosbøl (E)

Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.

Christian Torp-Pedersen (C)

Department of Clinical Research, Nordsjaellands Hospital, Hillerørd, Denmark.

Morten Schou (M)

Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Denmark.

Lars Køber (L)

Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.

Kristian Kragholm (K)

Unit of Clinical Biostatistics and Epidemiology, Aalborg University Hospital, Aalborg, Denmark.
Department of Cardiology, North Denmark Regional Hospital, Denmark.
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Charlotte Andersson (C)

Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Denmark.
Department of Medicine, Section of Cardiovascular Medicine, Boston Medical Center, Boston University, Boston, MA, USA.

Tor Biering-Sørensen (T)

Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Denmark.
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Helle Collatz Christensen (HC)

Danish Clinical Quality Program (RKKP), National Clinical Registries, Copenhagen, Denmark.
Copenhagen Emergency Medical Services, The Capital Region of Denmark, Ballerup, Denmark.

Mikkel Porsborg Andersen (MP)

Department of Clinical Research, Nordsjaellands Hospital, Hillerørd, Denmark.

Gunnar Gislason (G)

The Danish Heart Foundation, Copenhagen, Denmark.
Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH